The Deal Meeting will bring together the most experienced deal-makers and business development executives in life sciences for an exclusive and invite-only meeting in a first-class and off-the-record setting.





Sponsors gain access in an intimate and private setting with life science industry top leaders and decision makers.

For additional information, please contact Susan Grayson at susan@crushlifesicences.com or sponsor@crushlifesciences.com.

AGENDA - October 16, 2019

8:00 – 8:45 am                          
Registration and Networking Breakfast

8:45 – 9:00 am                          
Welcome and Opening Remarks

9:00 - 10:30 am
KEYNOTE: Guhan Subramanian, The Joseph Flom Professor of Law and Business at The Harvard Law School and the Douglas Weaver Professor of Business Law at The Harvard Business School
Author of Negotiauctions: New Dealmaking Strategies for a Competitive Marketplace

10:30 - 11:00 am
Networking Break

11:00 - 11:45 am
Makings of M&A: Tactics and Strategies of The Deal
Deals don’t just happen, they are made. And the skills to make them are the most critical aspect—and take talent and diligence from all parties involved. M&A is a well-choreographed dance among CEOs and bankers. A valuable company or asset will only take you so far, and the devil in the details has to be considered and well managed.  From creating demand and then holding out for the best offer, knowing what to say to whom and when will lead you to the best deal. This session will offer insights from experienced dealmakers.
John Cox, former CEO, Bioverativ; Barbara Fox, former CEO, Tilos Therapeutics; Steve Sands, Vice Chairman Investment Banking and Chairman Global Healthcare Group, Lazard
Moderator: Rachael Bushey, Partner & Chair of Health Sciences, Pepper Hamilton, LLP

11:45 - 12:30 pm
All in The Family: The Role and Impact of Family Office Investing on Life Sciences
With the rise of venture creation firms and a shift in the capital market landscape, companies are increasingly turning to family offices as an alternative source of capital. At the same time, many family offices are looking to life science companies for investment opportunities. They especially can be a great source of capital during early raises, but finding them means getting the right introductions and then being prepared to pitch to their interest, establish trust, and maintain the relationship for the future. Find out how to start your search, manage the challenges presented by some inexperienced but well-meaning investors, and work with the savvy ones by hearing insights directly from experts on both sides the deals.
Dharminder Chahal, Investment Manager, Van Herk Investments & CEO, SkylineDx; Alex Shlyankevich, Millhouse; Nolan Sigal, Partner, Satter Investment Management
Moderator: Geoff Meyerson, Co-Founder and CEO, Locust Walk

12:30 - 1:30 pm
Networking Lunch




1:30 - 2:15 pm
Highway to Healthcare: How AI is Going to Change the Life Science Industry
Artificial Intelligence and machine learning are increasingly being incorporated into healthcare and life sciences. But let’s turn down the buzz and talk about the practicalities. From imaging to drug development, these technologies have the potential to greatly impact and transform the industry, or to be a set of shiny objects that add little value at the next inflection. Hear about the latest in AI and how it may impact your business—including your ability to conduct deals—in the future.
Arnaub Chatterjee, Senior Vice President-Product and Ecosystem, Acorn AI, Medidata Solutions; Peter Henstock, Machine Learning & AI Technical Lead, Pfizer; Neil Tenenholtz, Senior Research Engineer, Microsoft Research
Moderator: Colin Hill, Chairman and CEO, GNS Healthcare

2:15 - 2:45 pm
Fireside Chat: Adventures in Deal-making
Michael Gilman,
Chairman and CEO, Arrakis Therapeutics
Moderator: Doug MacDougall, Managing Partner, MacDougall Biomedical Communications

2:45 - 3:00 pm
Networking Break

3:00 - 3:45 pm
More Money, More Problems? Capital Efficiency vs Mega Millions
With venture investors trending towards company creation, some early stage companies may find it more difficult to raise $10 million vs the $100 million mega rounds seen recently. Yet with great capital comes great responsibility. Generating a return on each of those investments comes with unique challenges, including allocating it to necessary vs potentially non-value added activities. We juxtapose capital efficient models with large financings and the impact on business models and return profiles.
Neil Exter, Partner, Third Rock Ventures; Emile Nuwaysir, President and CEO, BlueRock Therapeutics; Peter Wirth, Venture Partner, Quan Capital
Moderator: Teresa Lavoie, Principal, Fish & Richardson

3:45 - 4:30 pm
Deep Dive: How A Complete Commercial Assessment Can Impact Your Deal
A commercial assessment is an essential part of any deal. Yet today’s diligence moves beyond just the science. From a changing payor landscape to new trends in patient dynamics, the depth of and timing of that assessment can greatly impact your transaction terms, and often the need for it is recognized and responded to is later than ideal. Build the due diligence package that delivers. 
Balazs Felcsuti, Vice President, Health Advances; Phil McGurk, Head of East Coast Business Development & Acquisitions, AbbVie; Jim Weissman, CBO, Dicerna Pharmaceuticals
Moderator: Laurie Halloran, President & CEO, Halloran Consulting Group

4:30 - 5:00 pm
CRUSHed It” Deal of the Year Award

5:00 - 6:00 pm
Networking Cocktail Reception



October 3, 2019 - KEYNOTE SPEAKERS


Dharminder Chahal

Dharminder Chahal is CEO and co-founder of SkylineDx a company based in Rotterdam, The Netherlands, developing diagnostic tests in oncology. He is also owner and managing director of Exponential BV in which capacity he acts as consultant to Van Herk Investments. Mr. Chahal has built an extensive network in the global life science industry and a strong track record in direct involvement of complex corporate transactions including the sale of the stake of Van Herk Investments in Crucell to Johnson and Johnson, the sale of deVGen to Syngenta and the sale of Ablynx to Sanofi. As a board member or advisor he has been and still is active for several European companies in the field of life sciences.

At present, Mr. Chahal is a supervisory board member of BioInvent, Sweden, a supervisory board member of VitalneXt, an advisory board member of BioGeneration Ventures II, Thuja Capital Fund I as well as Gilde Healthcare Funds II and III. Mr. Chahal previously held various positions in investment banking and asset management, including Kempen & Co and Robeco. Mr. Chahal obtained a master degree in Business Economics (Erasmus University Rotterdam) and a master degree cum laude in Aerospace Engineering (TU Delft).


Guhan Subramanian

Guhan Subramanian is the Joseph Flom Professor of Law and Business at the Harvard Law School and the Douglas Weaver Professor of Business Law at the Harvard Business School. He is the first person in the history of Harvard University to hold tenured appointments at both HLS and HBS. At HLS he teaches courses in negotiations and corporate law. At HBS he teaches in several executive education programs, such as Strategic Negotiations, Making Corporate Boards More Effective, and the Advanced Management Program. He is the faculty chair for the JD/MBA program at Harvard University, the Harvard Program on Negotiation, and the Mergers & Acquisitions executive education course at HBS. Prior to joining the Harvard faculty he spent three years at McKinsey & Company.

Professor Subramanian's research explores topics in corporate law, corporate governance, and negotiations. He has published articles in the Stanford Law Review, the Yale Law Journal, the Harvard Business Review, and the Harvard Law Review, among other places. Eleven of his articles have been selected as being among the “top ten” articles published in corporate and securities law in their respective years, among the 400+ articles that are published each year, by scholars in the field. The two-volume treatise Law & Economics of Mergers & Acquisitions, which includes 33 “seminal” articles from the field over the past 45 years, contains four of his articles, more than from any other scholar. His article “Corporate Governance 2.0” was selected as a McKinsey Award finalist, for best article published in the Harvard Business Review in 2015. His book Dealmaking: The New Strategy of Negotiauctions synthesizes the findings from his research and teaching from the past two decades. It has been translated into Chinese (Mandarin), German, Japanese, Portuguese, and Spanish. He is also a co-author of Commentaries and Cases on the Law of Business Organization, a leading textbook in the field of corporate law. 

Professor Subramanian has been involved in major public-company deals such as Cox Enterprises’ $9 billion freeze-out of the minority shareholders in Cox Communications, Exelon’s $8 billion hostile takeover bid for NRG, and the $26 billion management buyout of Dell, Inc. He also advises individuals, boards of directors, and management teams on issues of dealmaking and corporate governance. Over his two decades on the Harvard faculty, Professor Subramanian has been involved as an advisor or expert witness in deals or situations worth over $150 billion in total value. He is a director of LKQ Corporation (NASDAQ: LKQ), a Fortune 500 company in the automotive sector. 

Professor Subramanian holds degrees in Law, Economics, and Business from Harvard University.